TABLE 1.
Trends in expenditure for OMPs and cumulative number of rare disease patients treated with OMPs per year.
| Year | % For OMPs from expenditure for all medicines | % Of exceptionally reimbursed OMPs from expenditure for all OMPs | Cumulative number of patients treated with accessible OMPs | Cumulative number of patients treated with exceptionally reimbursed OMPs | Cumulative number of patients treated with OMPs |
|---|---|---|---|---|---|
| 2010 | 2.8 | 2.2 | 1,405 | 44 | 1,449 |
| 2011* | 3.4 | 4.7 | 1,739 | 72 | 1,811 |
| 2012 | 3.7 | 8.1 | 1,781 | 58 | 1,832 |
| 2013 | 3.2 | 17.2 | 1,375 | 108 | 1,483 |
| 2014 | 3.6 | 17.2 | 1,527 | 152 | 1,679 |
| 2015 | 3.7 | 23.4 | 1,552 | 231 | 1,783 |
| 2016 | 4.2 | 27.0 | 1,583 | 295 | 1,878 |
| 2017 | 4.2 | 20.8 | 1,635 | 309 | 1,944 |
| 2018** | 4.7 | 15.0 | 1,873 | 309 | 2,182 |
| 2019** | 5.3 | 14.2 | 1,926 | 271 | 2,197 |
* New pricing and reimbursement Act, ** Novelization of the pricing and reimbursement Act.